86 related articles for article (PubMed ID: 38423172)
1. Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology.
Elemam NM; Mekky RY; Rashid G; Braoudaki M; Youness RA
Expert Rev Mol Med; 2024 Jan; 26():e1. PubMed ID: 38186186
[TBL] [Abstract][Full Text] [Related]
2. Interleukine-10 in ovarian cancer.
Levin G; Gotlieb WH
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38735685
[TBL] [Abstract][Full Text] [Related]
3. Paracrine Regulation and Immune System Pathways in the Inflammatory Tumor Microenvironment of Lung Cancer: Insights into Oncogenesis and Immunotherapeutic Strategies.
Batrash F; Shaik A; Rauf R; Kutmah M; Zhang J
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539448
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
5. [Interleukin-34: a key molecule in the tumor microenvironment].
Kajihara N; Seino KI
Rinsho Ketsueki; 2021; 62(8):1302-1307. PubMed ID: 34497220
[TBL] [Abstract][Full Text] [Related]
6. Exploring the multifaceted effects of Interleukin-1 in lung cancer: From tumor development to immune modulation.
Tang M; Yin Y; Wang W; Gong K; Dong J; Gao X; Li J; Fang L; Ma J; Hong Y; Li Z; Bi T; Zhang W; Liu W
Life Sci; 2024 Apr; 342():122539. PubMed ID: 38423172
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
Castillo DR; Jeon WJ; Park D; Pham B; Yang C; Joung B; Moon JH; Lee J; Chong EG; Park K; Reeves ME; Duerksen-Hughes P; Mirshahidi HR; Mirshahidi S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511306
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
9. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Nasser MW; Elbaz M; Ahirwar DK; Ganju RK
Cancer Lett; 2015 Aug; 365(1):11-22. PubMed ID: 25963887
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
